Viridian Therapeutics, Inc.VRDNNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
62.52%
↑ 232% above average
Average (39q)
-47.25%
Historical baseline
Range
High:79.56%
Low:-1574.64%
CAGR
+6.4%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | 62.52% |
| Q2 2025 | -13.74% |
| Q1 2025 | -7.31% |
| Q4 2024 | -4.78% |
| Q3 2024 | -15.64% |
| Q2 2024 | -29.14% |
| Q1 2024 | 21.80% |
| Q4 2023 | -39.54% |
| Q3 2023 | 13.58% |
| Q2 2023 | 18.21% |
| Q1 2023 | -47.71% |
| Q4 2022 | -64.73% |
| Q3 2022 | -0.75% |
| Q2 2022 | -14.20% |
| Q1 2022 | 10.98% |
| Q4 2021 | -105.75% |
| Q3 2021 | 21.47% |
| Q2 2021 | 2.79% |
| Q1 2021 | 79.56% |
| Q4 2020 | -1574.64% |
| Q3 2020 | 15.12% |
| Q2 2020 | 20.31% |
| Q1 2020 | 20.58% |
| Q4 2019 | 10.32% |
| Q3 2019 | -25.59% |
| Q2 2019 | 23.81% |
| Q1 2019 | -12.27% |
| Q4 2018 | -14.23% |
| Q3 2018 | -3.27% |
| Q2 2018 | -91.84% |
| Q1 2018 | 27.31% |
| Q4 2017 | -7.90% |
| Q3 2017 | 19.88% |
| Q2 2017 | -5.92% |
| Q1 2017 | -26.79% |
| Q4 2016 | -201.38% |
| Q3 2016 | 26.89% |
| Q2 2016 | 9.18% |
| Q1 2016 | 7.51% |
| Q4 2015 | 5.47% |